News Update

NeoImmuneTech and NIAID Embark on a Collaborative Study to Explore New Treatment for Acute Radiation Syndrome (ARS)


NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced the commencement of a groundbreaking study with the National Institute of Allergy and Infectious Diseases (NIAID). This collaboration will explore the potential of NT-I7 (efineptakin alfa) (rhIL-7-hyFc) in the treatment of Acute Radiation Syndrome (ARS).


Building on the previous announcement of the non-clinical evaluation agreement between NeoImmuneTech, Inc. and the National Institute of Allergy and Infectious Diseases (NIAID), signed end of 2022, a study plan has been designed to test NT-I7 in NIAID’s established ARS rodent models. The study has now started. This initiative not only underscores the commitment of both NeoImmuneTech and NIAID in the fight against ARS but also represents a major step towards developing NT-I7 as a medical countermeasure for this life-threatening condition.


ARS is an acute illness caused by irradiation of most of the body by a high dose of penetrating radiation in a short period of time. In the face of radiation exposure, recovery of the T cell compartment poses a significant challenge, with current therapies offering limited relief. By potentially addressing this gap, NT-I7 may represent a critical advancement in ARS treatment.



About Acute Radiation Syndrome (ARS)

Acute Radiation Syndrome (ARS) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (typically a matter of minutes or less). Examples of people who suffered from ARS are individuals exposed during the Hiroshima and Nagasaki atomic bombings, and the firefighters that responded after the Chernobyl Nuclear Power Plant incident in 1986.


About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)

NT-I7 (efineptakin alfa) (rhIL-7-hyFc) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.


About NeoImmuneTech, Inc. (NIT)
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit


Forward-looking Statements

The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.

Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.


Media inquiries :